NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

ex,



Any commercially successful DC technology would be good news for NWBO and further proof of concept, and the world is big enough to have more than one company in the DC business. Markets such as the U.S. and U.K. have regulatory gatekeepers that do not allow pharmaceuticals that aren’t approved by the governments of those nations.

Consider for example how many PD1 drugs exist today.

DC technologies available in countries like India, Germany, and Mexico are sold in less regulated environments. NWBO’s DCVax-L is differentiated by its larger-scale P3 clinical trial and NWBO is aiming for broad regulatory approval in the U.K. and in the U.S. when automated manufacturing is scalable. DCVax-L is a novel product that has been rigorously tested.

As an aside, the novel DC technology that is under investigation at Roswell in a randomized controlled trial is funded by a peer-reviewed grant from the U.S. DoD, and the RCT at UCLA is funded by continuing peer-reviewed grants from the U.S. NIH. The U.S. has great DC technology right here at our own world-renowned research institutions.

Clinically tested novel combinations are perhaps the most significant factor that sets NWBO apart from others (PD1 combos are being developed at both UCLA & Roswell).

The novel DCVax-L cell-based platform and EDEN are both patent-fortified technologies owned by Northwest Biotherapeutics in addition to the Roswell DC technology that is also licensed to NWBO, but nobody is suggesting that NWBO’s dominant position reflects a zero-sum game. NWBO will protect its intellectual property and proprietary processes, but the success of other clinical studies involving DC technology would be a positive indicator for DCVax-L and NWBO does not need to block everyone else on Earth from approaching the immunotherapy market.

For example, consider the success of Keytruda and all the other checkpoint inhibitors that have joined the market or that are emerging now… it’s been great for the field of oncology and great for the vast possibilities of combos as clinical investigations are imagined by several research institutions and industry players, and then commenced with real patients.

PD-1 technology has only been commercialized for 10 years since September 2014, and the PD-1 market has become huge. Partnerships and collaborations are born of new innovations, and the benefits are realized by more than just a single company.

⭐️Combo is King!⭐️

“Dendritic cell (DC) vaccines have strong potential to become a standard combination with **PD-1 inhibitors** across many types of cancer due to the complementary mechanisms of action between these two approaches. Here’s why this combination is relevant to a broad and expanding immunotherapy market:

### 1. **Synergistic Mechanisms**:
- **PD-1 inhibitors** like pembrolizumab (Keytruda) block the **immune checkpoint** pathway that tumors use to evade immune attacks, effectively releasing the "brakes" on T-cells.
- **Dendritic cell vaccines** prime and activate T-cells by presenting tumor antigens, boosting the initial immune response. This combination can lead to an enhanced anti-tumor response by both activating more immune cells (via the vaccine) and unleashing them on cancer cells (via PD-1 inhibition).

This synergy is promising because **PD-1 inhibitors** work better in an environment where T-cells have already been activated, and **DC vaccines** can increase the number of tumor-specific T-cells ready to attack the cancer (https://www.nature.com/articles/s41416-023-02194-1.pdf).

### 2. **Evidence from Early Studies**:
- Preliminary clinical trials have shown promising results when **DC vaccines** are combined with **checkpoint inhibitors**. For instance, a study combining a **dendritic cell vaccine** with **nivolumab** (a PD-1 inhibitor) in **glioblastoma patients** indicated improved outcomes compared to using either treatment alone. This suggests that DC vaccines can increase the efficacy of PD-1 blockade therapies by priming the immune system.
(A Phase III Clinical Trial Evaluating DCVax-L, Autologous Dendritic Cells (DC) Pulsed with Tumorlysate Antigen for the Treatment of Glioblastoma Multiforme (GBM) Dana-Farber Cancer Institute (https://www.dana-farber.org/clinical-trials/13-354)

### 3. **Potential Across Cancer Types**:
- Given that **PD-1 inhibitors** are approved for multiple cancer types, including melanoma, lung cancer, and renal cell carcinoma, the addition of **dendritic cell vaccines** could enhance immune activation across many of these cancers. Since DC vaccines can be designed to target specific tumor antigens, they offer **personalization** while still being versatile enough for combination with existing PD-1 inhibitors across a broad range of tumors.

### 4. **Long-Term Immune Memory**:
- **DC vaccines** can potentially create **long-term immune memory**, teaching the immune system to recognize and respond to tumor cells even after treatment. Combining this with **PD-1 inhibitors** could help maintain a more durable and sustained anti-cancer response, reducing the likelihood of relapse.

### 5. **Expanding Clinical Research**:
- Ongoing clinical trials are investigating the combination of **dendritic cell vaccines** with PD-1 inhibitors in various cancers, including **glioblastoma**, **ovarian cancer**, and **melanoma**. If these trials continue to show improved efficacy and safety, this combination could become a standard approach in oncology (https://www.nature.com/articles/s41416-023-02194-1.pdf).

### Conclusion:
The combination of **dendritic cell vaccines** with **PD-1 inhibitors** has strong potential to become a standard treatment in cancer therapy due to the synergy between activating T-cells (via the vaccine) and releasing immune suppression (via PD-1 blockade). As more clinical trials are conducted and manufacturing technologies improve (such as with the **EDEN** platform from Northwest Biotherapeutics), this approach may expand across a wide range of cancer types.”

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175149927